Targeted delivery of anti-cancer agents to cancer cells is a mature line of investigation that has yet to realize its full potential. In this study we report on the development of a delivery platform with the future goal of merging two thus far parallel methods for selective elimination of cancer cells: targeted nanospheres and pretargeted radioimmunotherapy. Several clinical trials have shown the promise of pretargeted radioimmunotherapy, which leverages the specificity of antibodies for targeted cell populations and delivers a localized dose of a biotinylated radionuclide that is most often administered following binding of a biotinylated antibody and streptavidin (StA) to the target cells. The work presented here describes the development of biotinylated nanospheres based on an ABA-type copolymer comprised of a tyrosine-derived oligomer as the B-block and poly(ethylene glycol) (PEG) A-blocks. The biotinylated nanospheres encapsulate paclitaxel (PTX) to the same extent as unbiotinylated nanospheres. Efficacy of targeting was shown on CD44 positive cells in the SUM159 breast cancer cell line by incubating the cells sequentially with a biotinylated anti-CD44 antibody, StA and the biotinylated nanospheres encapsulating PTX. Targeted nanospheres achieved the half maximal inhibitory concentration of PTX on SUM159 cells at a 5-10 fold lower concentration than that of PTX applied in either non-targeted nanospheres or free drug approaches. Moreover, targeted nanospheres selectively eliminated CD44 positive SUM159 cells compared to free PTX and untargeted nanospheres. This new generation of nano-sized carrier offers a versatile platform that can be adopted for a wide variety of drug and target specific applications and has the potential to be combined with the clinically emerging method of pretargeted radioimmunotherapy.
Introduction
Drug delivery via nanoparticle-based carriers has shown promising pharmacological results for cancer therapy. Paclitaxel-(PTX) containing nanoparticles have been approved by the FDA for breast cancer treatment (Abraxane®) and several nanoparticulate formulations containing various chemotherapy drugs, such as PTX, doxorubicin (DOX), and cisplatin are currently in clinical trials [1, 2] . Among the biomaterials applied as the matrix of nano-sized drug carriers, focus has been given to copolymers where both chemical composition and supramolecular structure can be adjusted to meet specific criteria. Amphiphilic block copolymers have particular promise since they self-assemble in aqueous environment and form a coreshell structure, enabling the encapsulation of the lipophilic drugs, prolonged circulation time, and protection against uptake by the reticuloendothelial system [3] [4] [5] [6] [7] .
A strategy to further improve the therapeutic efficacy of drugcontaining nanoparticles is to functionalize them with targeting ligands that have affinities for specific types of cells or tissues. Successful targeting will result in a specific concentration of the drug-containing carriers at the intended site of delivery in a more precise manner as compared to the passive accumulation of the nanocarriers due to the enhanced permeability and retention (EPR) effect [8] . Targeted delivery is hypothesized to help overcome aspects of drug resistance in chemotherapy [9] . Targeting typically involves covalent binding of a ligand to the nanocarrier [10] , and several recent examples of ligands are lectin to target intestinal M-cells [11] , A10 aptamer for prostate cancer cells [12] , folic acid to target ovarian A2780 cells [13] and Hela cells [14] , and RGD for metastatic cancer cells [15] .
An additional method of cancer targeting is through pretargeted radioimmunotherapy. Pretargeted radioimmunotherapy is a versatile targeting method, where antibodies against cancer cells are used as the targeting motif and first injected into the patient [16] . Commonly, such antibodies are either directly conjugated with streptavidin (StA) (or other biotin-binding proteins) or biotinylated so that subsequently injected StA will bind to the biotinylated antibody. As StA has four distinct and cooperative binding sites for biotin [17] , it serves as the docking platform to bind radiolabeled biotin that then accumulates on the targeted cell. Several promising clinical trials have shown the safety and efficacy of this targeting method [18] [19] [20] [21] [22] [23] [24] [25] .
We have set out to develop a drug-delivery platform that leverages the advancements in pretargeted radioimmunotherapy and could be used instead of or in combination with radiolabeled biotin. The basis of the platform is tyrosine-derived nanospheres (Tyr-NSP) composed of block copolymers of desaminotyrosyl tyrosine octyl ester and suberic acid oligomer (oligo(DTO-SA)) and PEG [26] . Previous reports documenting the Tyr-NSP showed encapsulation of hydrophobic molecules such as vitamin D3 [27] , PTX [28] [29] [30] and a variety of fluorescent dyes [29] . Tyr-NSP displayed negligible toxicity in vitro [26] and in vivo [31] . Biotinylation of Tyr-NSP was accomplished through the attachment of a heterobifunctional PEG to the oligo(DTO-SA), which introduced free carboxylic acid end groups to the polymer chain, providing a platform for the attachment of the biotin targeting moiety. Biotinylated Tyr-NSP (bTyr-NSP) were capable of binding StA, encapsulating PTX and showed improved efficacy at killing CD44 positive SUM159 cancer cells in vitro when combined with a biotinylated anti-CD44 antibody and StA modeled after what is employed with pretargeted radioimmunotherapy.
Materials and methods

Materials
Methylene chloride (HPLC grade), acetic acid, N,N-dimethylformamide (DMF), tetrahydrofuran (THF), 2-propanol and Ez-Link Amine-PEG 2 -Biotin (MW = 374.5) were purchased from Fisher Scientific (Pittsburgh, PA). Suberic acid (SA), cetyltrimethylammonium bromide (CTAB), N,N′-dicyclohexylcarbodiimide (DCC), hydroxybenzotriazole (HOBT), and phosphate buffered saline (PBS) were purchased from Aldrich Chemical Co. (Milwaukee, WI). N-hydroxysuccinimide (NHS) was purchased from Acros Organics (Geel, Belgium). Diisopropylcarbodiimide (DIPC) was purchased from Tanabe Chemicals (San Diego, CA). The heterobifunctional PEG, NH 2 -PEG-COOH (5000 Da from the product specification; weight average molecular weight Mw = 4.0 kDa as measured by GPC) was purchased from Laysan Bio (Arab, AL). Desaminotyrosyltyrosine octyl ester (DTO), 4-dimethylaminopyridinium-p-toluene sulfate (DPTs) and DTO-SA/PEG 5K (Mw =~27 kDa) were synthesized using published procedures [29] . All chemicals were used as received.
Analytical techniques and used instrumentation
1 H NMR spectra were recorded on a Varian VNMRS 500 MHz (Agilent, Santa Clara, CA) at 25°C. 1 H NMR spectra were calibrated to the solvent signal of DMSO-d 6 (δ = 2.50 ppm). Chemical shifts were provided in ppm. The following abbreviations for the peak multiplicities were used: s, singlet; d, doublet; dd, double doublet; t, triplet; q, quadruplet; m, multiplet; br, broad. GPC system consisted of a 515 HPLC pump, a 717 plus autosampler, 410 RI detector, and Empower 2 software (Waters Corporation). Two PL gel columns 10 3 and 10 5 Å (Polymer Laboratories/ Agilent, Santa Clara, CA) were used in series with THF as the mobile phase at a flow rate of 1 mL/min. The system was calibrated with polystyrene standards (Polymer Laboratories/Agilent, Santa Clara, CA).
Synthesis of the triblock copolymer
The triblock copolymer, HOOC-PEG-oligo(DTO-SA)-PEG-COOH, was synthesized in a three step reaction process: synthesis of the hydrophobic core oligo(DTO-SA), NHS esterification of the carboxylic acid end groups, followed by the attachment of the heterobifunctional PEG (NH 2 -PEG-COOH).
Synthesis of oligo(DTO-SA)
Oligo(DTO-SA) was prepared by a DIPC and DPTs-catalyzed reaction of DTO and SA. The reaction was quenched with CTAB and water. The oligomer was purified and the molecular weight (Mw = 22 kDa and Mn = 15 kDa, by GPC) and the 1 H-NMR spectrum of the compound obtained were found to be identical to oligo(DTO-SA) as previously described [28] .
2.3.2. NHS esterification of oligo(DTO-SA) (Fig. 1, Product 1) 500 mg (3.33 × 10 − 5 mol) of oligo(DTO-SA), 10.5 mg (9.12 × 10 − 5 mol) of NHS, and 3 mL of methylene chloride were combined in a 25 mL round-bottom flask. With continuous stirring at room temperature, 16 μL of DIPC was added to the mixture. After 2 h, the reaction was quenched by the addition of 9 μL of acetic acid and allowed to stir for 20 min. Product 1 was isolated by precipitation in 2-isopropanol and purified as described before [28] . 3 of the octyl pendant chain in the DTO). Based on the integration of NMR peaks, 89% of the carboxylic acid groups on Product 2 were biotinylated.
Preparation of biotinylated nanospheres
Self-assembly of the biotinylated polymers into nanospheres (bTyr-NSP) was induced by drop-wise addition of 150 mg/mL of Product 3 and non-biotinylated DTO-SA/PEG 5K (1:3 w/w) in DMF solution into 0.1 M PBS (pH 7.4) under mild agitation. Preparation and characterization of Tyr-NSP and bTyr-NSP were carried out as previously reported [29] .
Verification of biotin accessibility
To confirm the accessibility of the biotin-targeting moiety on bTyr-NSP in aqueous suspension, 300 μL of bTyr-NSP or Tyr-NSP suspensions (polymer content approximately 10 mg/mL) were incubated for 30 min at room temperature with 200 μL PBS solution containing 0, 10, 50 and 100 μg of FITC-conjugated Streptavidin (FITC-StA, Invitrogen, Carlsbad, CA). The mixtures were centrifuged at 65,000 rpm for 3 h and the pelleted bTyr-NSP and Tyr-NSP were re-dispersed in PBS. The fluorescence intensity (excitation/emission wavelengths at 488 nm/519 nm) was recorded with Tecan Infinite M200 PRO microplate reader. PBS was used as internal standard and the relative fluorescence intensity was reported as the ratio between the fluorescence intensity of the test sample and that of PBS. 4 independent experiments were performed.
Paclitaxel-loaded nanospheres
Preparation and characterization of paclitaxel-loaded tyrosinederived nanospheres (Tyr-NSP-PTX) and paclitaxel-loaded biotinylatedtyrosine-derived nanospheres (bTyr-NSP-PTX) were performed according to previously established procedure [32] with the following modification: the feed ratio between the PTX and triblock copolymer changed to 1% w/w. The binding and loading efficiencies of PTX by bTyr-NSP and Tyr-NSP were determined using previously reported extraction and HPLC techniques [30, 32] .
Cell culture
SUM159 human breast carcinoma cells were obtained courtesy of Dr. Prabhas Moghe at Rutgers, The State University of New Jersey. SUM159 cells were cultured in media consisting of Ham's F12 (Invitrogen, Carlsbad, CA), 5 μg/mL bovine pancreas insulin (Sigma Aldrich, Milwaukee, WI), 1 μg/mL hydrocortisone, 10 mM HEPES (Lonza, Allendale, NJ), 1 × Penicillin:streptomycin (Fisher Scientific, Pittsburgh, PA), and 5% fetal bovine serum, FBS (Atlanta Biologicals, Lawrenceville, GA). Cells were maintained at sub-confluent levels with media changes every 2-3 days.
Cell targeting and immunocytochemistry
SUM159 cells were plated at a density of 5000 cells per well onto 12 mm glass cover slips in a 24-well plate and incubated overnight. Biotinylated anti-CD44 (eBioscience, San Diego, CA) antibody was added to cells at manufacturers recommended dilution (1:50 v/v) in the media without FBS and incubated on cells for 30 min followed by media removal. StA was then added to the wells at a 5-fold molar excess of the antibody concentration and incubated for another 30 min. Cells were gently washed twice with pre-warmed Dulbecco's phosphate buffered saline (dPBS) and PTX-containing biotinylated nanospheres (bTyr-NSP-PTX) were added in with FBS containing media. Various conditions were tested with cultures treated identically but substituting the control treatments for bTyr-NSP-PTX. Following addition of treatments, cells were cultured for an additional 72 h at which point the cells were gently washed with pre-warmed dPBS and fixed with 2% paraformaldehyde for 15 min. Cover slips were blocked with a solution containing 20% donor calf serum and then immuno-stained for CD44 (1:100 dilution) followed by an Alexa Fluor®-488 secondary antibody (Invitrogen, Carlsbad, CA), stained with a Hoechst and fluorescent microscopy was used to count and determine the number of surviving CD44 positive and CD44 negative cells that did not show DNA fragmentation characteristic of PTX induced cell death [33] .
Cell viability assays
SUM159 cells were plated at a density of 3000 cells per well into 96-well plates and allowed to adhere overnight. The following day, cells were targeted as described above and allowed to culture for 72 h. Cells were gently washed twice with pre-warmed dPBS and then media containing 10% v/v AlamarBlue® reagent (Fisher) were placed into the wells and absorbance readings were taken to determine reduction of resazurin into resorufin. Wells given bTyr-NSP without cells and washed twice with the pre-warmed dPBS showed that there was no effect of the nanospheres on AlamarBlue®. At least 3 independent experiments were performed and results were % normalized to the control of no PTX and are presented as a mean value with its standard error indicated (mean ± SEM).
Statistics
All data are the result of at least 3 independent experiments and are presented as mean ± SEM. The Student's t-test was used to determine statistical significance with * denoting p b 0.05, ** p b 0.005, and *** p b 0.0005.
Results
Synthesis
The rationale for the synthetic route outlined in Fig. 1 was to produce tyrosine-derived triblock copolymer with free carboxylic acid groups on the end of the hydrophilic PEG blocks. Provided that the targeting ligand has an available reactive amine group, the covalent attachment of a wide variety of functional moieties to this polymer can be achieved via amide bond formation.
With the successful synthesis of HOOC-oligo(DTO-SA)-COOH according to published procedures [28] , heterobifunctional PEG was then conjugated in two separate steps. First, the carboxylic acid ends of the oligomer were activated using NHS (Product 1). In the second step, amide bonds were formed between the oligo(DTO-SA) block and the amine-terminated heterobifunctional PEG (Product 2). This two-step procedure ensured that Product 2, the amphiphilic triblock copolymer, had reactive carboxylic acid end groups. GPC analysis of Product 2 showed an increase of 8 kDa in Mw (Mw of 30 kDa and Mn of 22 kDa) relative to HOOC-oligo(DTO-SA)-COOH, which is in agreement with the attachment of 2 blocks of NH 2 -PEG-COOH (Mw 4 kDa) to both sides of the oligomer. The PEGylation was further confirmed by 1 H NMR analysis. Product 2 with two PEG-COOH segments at the termini now contains reactive groups that enable attachment of a wide variety of molecules via the formation of a new amide bond. To verify this possibility and attach additional groups to Product 2, we utilized a commercially available biotinylation reagent containing a short spacer and a primary amine (EZ-Link Amine-PEG 2 -Biotin). This molecule was attached to Product 2 using DCC as coupling agent to yield Product 3, as confirmed by 1 H NMR. This validated the proposed synthetic route.
Formation of bTyr-NSP and Tyr-NSP
To determine whether this modification of the PEG end blocks affected self-assembly into nanospheres, Product 3 was mixed with non-biotinylated DTO-SA/5 K at a 1:3 w/w ratio in DMF, and added to PBS to form nanospheres using established procedures [26, 28, 32] . Hydrodynamic diameters of resulting bTyr-NSP and control Tyr-NSP were 64.1 ± 0.5 and 63.8 ± 1.2 nm, respectively, indicating that the presence of the biotin moiety did not significantly affect the assembly and size distribution of the nanospheres.
The incorporation of biotin was designed to act as a means to tether a variety of functional moieties onto bTyr-NSP via the biotin-StA interaction. StA contains four discreet biotin-binding sites and binds biotin at exceptionally high affinity in a cooperative fashion [17] . As biotin is relatively hydrophobic, the accessibility of biotin molecules on the surface of the nanospheres is a key issue. To assess this question, bTyr-NSP and Tyr-NSP were separately incubated with fluorescently labeled StA (StA-FITC). Following 30 min of incubation, the bTyr-NSP/FITC-StA and Tyr-NSP/FITC-StA were centrifuged and the unbound StA-FITC in the supernatant was removed. The fluorescence intensity of the re-suspended bTyr-NSP and Tyr-NSP was measured and compared with that of PBS as a control. The relative fluorescence intensity values compared to PBS were plotted against the applied StA-FITC amount (Fig. 2) .
Without adding StA-FITC, both Tyr-NSP and bTyr-NSP showed no difference as compared to PBS (relative fluorescence intensity = 1.03 ± 0.03 and 1.05 ± 0.05, respectively). Tyr-NSP showed a slight increase in the relative fluorescence intensity with the applied amount of StA-FITC (relative fluorescence intensity values ranged between 1.4 and 3.9 when 10-100 μg of StA-FITC were applied), indicating weak non-specific binding of StA-FITC onto the Tyr-NSP surfaces. The binding of StA-FITC to bTyr-NSP was clearly illustrated as the relative fluorescence intensity values increased substantially with the dose of StA-FITC (Fig. 2). 
Loading of PTX into Tyr-NSP and bTyr-NSP
To investigate whether the addition of biotin affected the ability of bTyr-NSP to encapsulate lipophilic drugs, PTX was loaded into bTyr-NSP and control Tyr-NSP using procedures previously reported [26] [27] [28] 32] . Loading and binding efficiencies of PTX into Tyr-NSP (Tyr-NSP-PTX) were 1.2 ± 0.2% and 45.0 ± 4.0% and for bTyr-NSP-PTX 1.2 ± 0.3% and 44.8 ± 6.5%, respectively. Thus, the measured binding and loading efficiencies for the encapsulation of PTX into bTyr-NSP were equivalent to the efficiencies obtained from the control Tyr-NSP confirming that the presence of the biotin moiety did not alter the drug encapsulation ability of the nanospheres.
Cell specific targeting in vitro
The ability of bTyr-NSP-PTX to target specific cell sub-populations was evaluated using SUM159 cells, a basal-type human primary breast cancer cell line. SUM159 cells are tumorogenic in murine xenograft studies and contain both CD44 positive and negative cells. While both CD44 positive and negative cells initiate tumors in xenograft studies, a CD44 positive sub-population of SUM159 cells show increased malignancy and chemoresistance compared to CD44 negative cells [34, 35] . A targeting protocol was developed based on the basic mechanism of biotin-StA interactions and consistent with clinical protocols for pretargeted radioimmunotherapy [16] . In our experimental setup, SUM159 cells were first incubated with a biotinylated anti-CD44 antibody then StA to create the pretargeting complex, followed by bTyr-NSP-PTX (Fig. 3) . Measurements of cell viability after 72 h of treatment showed that bTyr-NSP-PTX coupled with this targeting approach effectively decreased the dosage of PTX necessary to eliminate 50% of the cell population (Fig. 4) . The half maximal inhibitory concentration (IC50) of SUM159 cells targeted by anti-CD44 + StA + bTyr-NSP-PTX occurred between 0.5 nM and 1 nM of PTX, compared to IC50 values between 1 nM and 10 nM measured for untargeted bTyr-NSP-PTX and Tyr-NSP-PTX in various forms. Untargeted experimental groups, such as StA + bTyr-NSP-PTX or anti-CD44 + StA + Tyr-NSP-PTX, were less effective than the targeted approach. It is also noteworthy that both bTyr-NSP-PTX and Tyr-NSP-PTX applied alone were more effective at eliminating SUM159 cells than free PTX. Finally, control experiments using equivalent amount of bTyr-NSP, but without PTX, following anti-CD44 and StA showed no cytotoxicity.
To assess the CD44 immunoreactivity of the surviving cell types after the 72 h treatment, SUM159 cells were subjected to varying doses of PTX, using both targeted and non-targeted formulations, and the immunoreactivity of the surviving cells was ascertained by immunocytochemistry using a fluorescent secondary antibody directed against the anti-CD44 primary antibody. Cells undergoing PTX-induced apoptosis showed a characteristic fragmenting of nucleic material, making apoptotic and non-apoptotic cells easily distinguishable using stains for DNA, such as Hoechst [33] .
As shown in Fig. 5 , the proportion of SUM159 cells without fragmented DNA and positive for CD44 following treatments with non-targeted bTyr-NSP-PTX or free PTX increased slightly with elevated doses of PTX. In contrast, when bTyr-NSP-PTX was targeted to CD44 positive cells using the biotinylated anti-CD44 antibody and StA, a selective decrease in the portion of cells without fragmented DNA that stained positive for CD44 was observed. This effect increased concurrent with elevated doses of targeted PTX delivery and first began to diverge from untargeted PTX conditions at a dose of 0.5 nM of PTX.
Discussion
These results suggest that the targeted delivery of PTX via bTyr-NSP-PTX not only enhanced the drug efficacy on killing SUM159 cells, but also selectively eliminated the CD44 positive cell population. Viability experiments (Fig. 4) confirmed that at PTX doses at or exceeding 10 nM for any treatment, very few viable cells remained. In nontargeted PTX treatments this correlates with an increase in the proportion of viable cells that stained positive for CD44 (Fig. 5C) , and is supported by previous reports that a subset of CD44 expressing cells within the SUM159 cell population are resistant to PTX treatment [34] . There is an increasing body of evidence showing that subsets of cells within cancer cell populations are both more capable of generating tumors as well as resistant to chemotherapy [36] . These results underscore the wider promise of nanoparticle-based delivery of chemotherapeutics to both preferentially target the most malignant cells within the tumor as well as attenuate adverse side effects [37] .
Selective elimination of CD44 positive cells using this targeting approach seems to be in line with this promise. In two of the experimental replicates, no CD44 positive cells without fragmented nuclei characteristic of PTX toxicity were observed at 25 nM and 50 nM of targeted PTX treatment. By using additional biotinylated antibodies, such as anti-epithelial-specific antigen (ESA), together with anti-CD44, it is likely possible to provide additional docking sites for bTyr-NSP-PTX on the most malignant cells within the SUM159 population. This may further increase the local concentration of PTX surrounding these cells and lower the effective dosage required to eliminate them.
Results from untargeted control conditions suggest the specificity of the targeted approach. Untargeted nanosphere formulations including bTyr-NSP-PTX, StA + bTyr-NSP-PTX did not selectively eliminate CD44 positive cells and were comparative to free PTX in their effects on the percentage of surviving SUM159 cells positive for CD44 (Fig. 5C) . Furthermore, the control group of targeted bTyr-NSP that did not contain PTX, anti-CD44 + StA + bTyr-NSP, showed no effects on overall viability or the proportion of cells positive for CD44. This indicates that the step-wise targeting scheme did not affect the cells in the absence of PTX.
A previous report by Pulkkinen et al. [38] also found an improvement in the ability to eliminate cells using a biotin-based targeting method. In that study, biotinylated poly(lactic acid) (PLA)-PEG nanospheres were enriched on the cellular surface of glioma cells via a biotinylated transferrin molecule connected to the PTX-containing PLA-PEG nanospheres using neutravidin as a linker. High expression of the transferrin receptor on glioma cells relative to most normal brain tissue is hypothesized to assist with enriching the PTXcontaining nanoparticles on tumors. The authors noted that a reduction in glioma cell viability was achieved in vitro through this targeting compared to untargeted approaches, but did not show a correlation between selective toxicity toward cells expressing transferrin.
The use of the presently described synthetic route for bTyr-NSP and the method of targeting have several layers of versatility. First, the triblock copolymers of DTO-SA/PEG 5K comprising the nanospheres can be modified to promote specific rates of drug release. This occurs either through changing the Mw of the hydrophobic or hydrophilic segments, or through altering the composition of the side chain within the hydrophobic desaminotyrosyl tyrosine (Fig. 1) . The current report utilizes octyl-ester for the side chain, whereas substitutions of dodecyl-ester or ethyl-ester greatly vary the drug loading and release kinetics [32] .
Secondly, the synthetic procedure described here for the tethering of biotin is likely to be efficacious for other targeting moieties with reactive primary amines, and may enable direct targeting independent of our current approach utilizing StA as the linkage to a biotinylated antibody. However, care must be taken to ensure that such moieties do not disrupt critical nanospheres properties as the polymer is modified prior to nanosphere formulation; such may be the case if the current scheme was adapted to directly attach the~150 kDa anti-CD44 antibody to the Tyr-NSP. Alternate chemistries have been reported that enable attachment of antibodies after formulation of nanospheres [39] and nanoparticles are routinely tethered to antibodies [40] . It is noteworthy that other groups have reported on the direct targeting using nanoparticles with smaller targeting moieties [10] [11] [12] [13] [14] [15] 41, 42] , including antibody fragments [43, 44] . Clinical success of directly targeted nanospheres is pending further optimization of these technologies [45] . The final layer of versatility comes from the use of the biotin-StA interaction as it relates to pretargeted radioimmunotherapy. Clinical studies have shown the efficacy of this method of co-localization against a wide variety of cancers, both solid and diffuse [18] [19] [20] [21] [22] [23] [24] [25] . This is possible simply by changing the antibody used to target the cells and is one of the beneficial aspects of a multi-component system. There are a growing number of antibodies approved for human use [46] and, importantly, StA appears to be well tolerated in cancer patients treated with pretargeted radioimmunotherapy even when injected multiple times over a period of months. A clearing agent is used to remove unbound antibody-StA complexes from circulation prior to administration of the biotin radionuclide and may play an important role in the specificity of accumulation [16] . The affinity of biotin for StA, with a dissociation constant (Kd) of 10 −14 to 10 −15 M [17] , is the strongest known non-covalent interaction and is orders of magnitude greater than most antibody-antigen interactions, which generally range between~10 −6 to 10 −9 M [47, 48] . By clearing unbound targeting complex, consisting of the antibody with StA, this means that the accumulation of the biotinylated anti-cancer component will be governed by the energetics of the biotin-StA and lowers the likelihood of accumulation the anti-cancer component in nontargeted areas. While experimentation reported here uses three-step targeting approach, it may be advantageous for future work, especially in animal models, to move to a two-step approach e.g. using preassembled antibody-StA conjugates as the pretargeting complex. Such two-step approaches are widely used in pretargeted radioimmunotherapy [25] . Using the conjugate pretargeting complex would cut down on the number of injections necessary to provide the treatment, while still benefitting from the high affinity of the biotin-StA interaction to dock the drug carrier biotinylated nanospheres and/or the radiolabeled biotin to the pretargeting complex on the target cell.
Conclusions
The ABA-type triblock copolymer consisting of a tyrosine-derived hydrophobic core and PEG hydrophilic corona was modified with a chemical procedure that enables the attachment of a wide variety of functional moieties. The attachment of Amine-PEG 2 -Biotin was presented in this work and biotin was applied as a model targeting motif. The biotinylated nanospheres loaded with PTX were successfully prepared and targeted to CD44 positive SUM159 breast cancer cells by sequentially exposing the cells to a biotinylated anti-CD44 antibody, StA and finally the biotinylated nanospheres containing PTX. This treatment showed a significantly enhanced cytotoxicity toward the SUM159 human breast carcinoma cells at the population level, but also showed preferential elimination of CD44 positive SUM159 cells. In this manner, a lower dose of PTX can be used to eliminate cancer cells and can increase the local concentration of PTX surrounding the most resistant CD44 positive cancer cells. This modification gives rise to a new generation of tyrosine-derived nanospheres as nano-sized drug delivery system offering versatility with respect to direct targeting, drug encapsulation, and compatibility with any of the clinically used antibody-based cancer therapies.
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